Business Context and Reporting Period
This Form 8-K, dated June 1, 2021, reports on AmerisourceBergen Corporation (now Cencora, Inc.). The filing details the completion of a strategic transaction with Walgreens Boots Alliance, Inc. (WBA) originally announced in January 2021. The reporting period focuses on the closing date of June 1, 2021.
Key Financial Metrics and Transaction Details
The primary financial event is the acquisition of a majority of WBA's Alliance Healthcare businesses. The total purchase price was approximately $6.5 billion, structured as follows:
- Cash Consideration: $6.275 billion (subject to customary purchase price adjustments).
- Equity Consideration: 2 million shares of Company common stock.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the Company or the acquired business within this text. Pro forma financial information and financial statements of the acquired business are scheduled to be filed by amendment within 71 calendar days of June 7, 2021.
Material Changes and Strategic Agreements
Beyond the acquisition, the Company entered into several material agreements with WBA effective June 1, 2021:
- Distribution Extension: A three-year extension through 2029 of the existing distribution agreement between WBA and the Company.
- Generic Drug Access: A three-year extension through 2029 of the arrangement providing access to generic drugs via Walgreens Boots Alliance Development GmbH.
- Boots UK Supply: A new distribution agreement to supply branded and generic pharmaceutical products to WBA's Boots UK Ltd.
- Shareholder Agreement: An Amended and Restated Shareholders Agreement was executed, increasing the percentage of outstanding common stock WBA and its affiliates are permitted to hold by 1%.
WBA's operations in China, Italy, and Germany were explicitly excluded from the transaction.
Guidance, Outlook, and Risks
On June 2, 2021, the Company issued a news release (Exhibit 99.1) discussing fiscal year 2021 guidance; however, the specific numerical guidance is not contained within the text of this filing. The filing notes that the information in Item 7.01 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Management commentary indicates the transaction is designed to create incremental growth and efficiencies in sourcing, logistics, and distribution. No specific risks or contingencies are detailed in the text of this report beyond standard references to purchase price adjustments.
Investor Verification Checklist
- Verify the final purchase price adjustments to the $6.275 billion cash component.
- Review the forthcoming pro forma financial information (due within 71 days of June 7, 2021) to assess the impact on leverage and liquidity.
- Examine the June 2, 2021 news release (Exhibit 99.1) for specific fiscal year 2021 revenue and earnings guidance.
- Confirm the integration timeline and expected synergies from the Alliance Healthcare acquisition.
- Monitor the impact of the increased shareholding limit for WBA on future corporate governance.